Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 4, 2005, Pages 1468-1476

  Fritsche, Thomas R ^a   Sader, Helio S ^a   Cleeland, Roy ^b   Jones, Ronald N ^a,c  

^a JMI LABORATORIES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [(FORMYLHYDROXYAMINO)METHYL]HEXANOYL]PYRROLIDINE 2 CARBOXYLIC ACID (5 FLUORO 1 OXY PYRIDIN 2 YL) AMIDE; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; OXACILLIN; PENICILLIN DERIVATIVE; PEPTIDE DEFORMYLASE INHIBITOR; RIFAMPICIN; STREPTOMYCIN; TEICOPLANIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; DRUG STRUCTURE; ENZYME INHIBITION; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDES;

EID: 16244411296     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.4.1468-1476.2005     Document Type: Article

References (34)

1. Adams, J. M. 1968. On the release of the formyl group from nascent protein. J. Mol. Biol. 33:571-589.
2. Anderegg, T. R., D. J. Biedenbach, R. N. Jones, and The Quality Control Working Group. 2003. Quality control guidelines for MIC susceptibility testing of NVP PDF-713, a novel peptide deformylase inhibitor. Int. J. Antimicrob. Agents 22:84-86.
3. Anderegg, T. R., R. N. Jones, and The Quality Control Working Group. 2004. Disk diffusion quality control guidelines for NVP PDF-713: a novel peptide deformylase inhibitor. Diagn. Microbiol. Infect. Dis. 48:55-57.
4. Apfel, C. M., H. Locher, S. Evers, B. Takacs, C. Hubschwerlen, W. Pirson, M. G. P. Page, and W. Keck. 2001. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob. Agents Chemother. 45:1058-1064.
5. Baquero, F. 1997. Gram-positive resistance: challenge for the development of new antibiotics. J. Antimicrob. Chemother. 39(Suppl. A):1-6.
6. Bowker, K. E., A. R. Noel, and A. P. McGowan. 2003. In vitro activities of nine peptide deformylase inhibitors and five comparator agents against respiratory and skin pathogens. Int. J. Antimicrob. Agents 22:557-561.
7. Chen, D. Z., D. V. Patel, C. J. Hackbarth, W. Wang, G. Dreyer, D. C. Young, P. S. Margolis, C. Wu, Z. J. Ni, J. Trias, R. J. White, and Z. Yuan. 2000. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39:1256-1262.
8. Clements, J. M., R. P. Beckett, A. Brown, G. Catlin, M. Lobel, S. Palan, W. Thomas, M. Whittaker, S. Wood, S. Salama, P. J. Baker, H. F. Rodgers, V. Barynin, D. W. Rice, and M. G. Hunter. 2001. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 45:563-570.
9. Credito, K., G. Lin, L. M. Ednie, and P. C. Appelbaum. 2004. Antistaphylococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4033-4036.
10. Deshpande, L. M., and R. N. Jones. 2003. Bactericidal activity and synergy studies of BAL9141, a novel pyrrolidinione-3-ylidenemethyl cephem, tested against streptococci, enterococci and methicillin-resistant staphylococci. Clin. Microbiol. Infect. 9:1120-1124.
11. Ednie, L. M., G. Pankuch, and P. C. Appelbaum. 2004. Antipneumococcal activity of LBM415, a new peptide deformylase inhibitor, compared with those of other agents. Antimicrob. Agents Chemother. 48:4027-4032.
12. Fritsche, T. R., G. J. Moet, and R. N. Jones. 2004. Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713, a novel inhibitor of bacterial peptide deformylase. Clin. Microbiol. Infect. 10:857-860.
13. Giglione, C., M. Pierre, and T. Meinnel. 2000. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol. Microbiol. 36:1197-1205.
14. Gordon, J. J., B. K. Kelly, and G. A. Miller. 1962. Actinonin: an antibiotic substance produced by an actinomycete. Nature 195:701-702.
15. Hackbarth, D. J., D. Z. Chen, J. G. Lewis, K. Clark, J. B. Mangold, J. A. Cramer, P. S. Margolis, W. Wang, J. Koehn, C. Wu, S. Lopez, G. Withers, H. Gu, E. Dunn, R. Kulathila, S. H. Pan, W. L. Porter, J. Jacobs, J. Trias, D. V. Patel, B. Weidmann, R. J. White, and Z. Yuan. 2002. N-Alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob. Agents Chemother. 46:2752-2764.
16. Hoellman, D. B., G. Lin, L. M. Ednie, A. Rattan, M. R. Jacobs, and P. C. Appelbaum. 2003. Antipneumococcal and antistaphylococcal activities of ranbezolid (RBX 7644), a new oxazolidinone. compared to those of other agents. Antimicrob. Agents Chemother. 47:1148-1150.
17. Jones, R. N. 2003. Global epidemiology of antimicrobial resistance among community-acquired and nosocomial pathogens: a five-year summary from the SENTRY Antimicrobial Surveillance Program (1997-2001). Semin. Respir. Crit. Care Med. 24:121-133.
18. Jones, R. N., and P. R. Rhomberg. 2003. Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J. Antimicrob. Chemother. 51:157-161.
19. Jones, R. N., T. R. Fritsche, and H. S. Sader. 2004. Antimicrobial spectrum and activity of NVP PDF-713, a novel peptide deformylase inhibitor, tested against 1,837 recent gram-positive clinical isolates. Diagn. Microbiol. Infect. Dis. 49:63-65.
20. Jones, R. N., G. J. Moet, H. S. Sader, and T. R. Fritsche. 2004. Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant gram-positive organism isolates. J. Antimicrob. Chemother. 53:804-807.
21. Knapp, C., and J. A. Moody. 1992. Tests to assess bactericidal activity, section 5.16. In H. D. Isenberg (ed.), Clinical microbiology procedures handbook. ASM Press, Washington, D.C.
22. Livingstone, D. M., and P. Leder. 1969. Deformylation and protein synthesis. Biochemistry 8:435-443.
23. Margolis, P., C. Hackbarth, S. Lopez, M. Maniar, W. Wang, Z. Yuan, R. White, and J. Trias. 2001. Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob. Agents Chemother. 45:2432-2435.
24. Margolis, P. S., C. J. Hackbarth, D. C. Young, W. Wang, D. Chen, Z. Yuan, R. White, and J. Trias. 2000. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob. Agents Chemother. 44:1825-1831.
25. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Approved standard M7-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. National Committee for Clinical Laboratory Standards. 2004. Performance standards for antimicrobial susceptibility testing, M100-S14. Supplemental tables. National Committee for Clinical Laboratory Standards, Wayne, Pa.
27. National Committee for Clinical Laboratory Standards. 2001. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 5th ed. Approved standard M11-A5. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. Approved guideline M26A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
29. Ribera, A., J. Ruiz, M. T. Jimenez de Anta, and J. Vila. 2002. Effect of an efflux pump inhibitor on the MIC of nalidixic acid for Acinetobacter baumunnii and Stenotrophomonas maltophilia clinical isolates. J. Antimicrob. Chemother. 49:697-702.
30. Roblin, P. M., and M. R. Hammerschlag. 2003. In vitro activity of a new antibiotic, NVP-PDF386 (VRC4887), against Chlamydia pneumoniae. Antimicrob. Agents Chemother. 47:1447-1448.
31. Thorarensen, A., M. R. Deibel, Jr., D. C. Rhorer, A. F. Vosters, A. W. Yem, V. D. Marshall, J. C. Lynn, M. J. Bohanon, P. K. Tomich, G. E. Zurenko, M. T. Sweeney, R. M. Jensen, J. W. Nielsen, E. P. Seest, and L. A. Dolak. 2001. Identification of novel potent hydroxamic acid inhibitors of peptidyl deformylase and the importance of the hydroxamic acid functionality on inhibition. Bioorg. Med. Chem. Lett. 11:1355-1358.
32. Waller, A. S., and J. M. Clements. 2002. Novel approaches to antimicrobial therapy: peptide deformylase. Curr. Opin. Drug Discov. Dev. 5:785-792.
33. Wise, R., J. M. Andrews, and J. Ashby. 2002. In vitro activities of peptide deformylase inhibitors against gram-positive pathogens. Antimicrob. Agents Chemother. 46:1117-1118.
34. Yuan, Z., J. Trias, and R. J. White. 2001. Deformylase as a novel antibacterial target. Drug Discov. Today 6:954-961.